In the era when obesity has been upgraded to an independent disease state, rather than a mere risk factor, such paradigm shifts suggest the TXNIP-NLRP3-inflammasome axis as a promising therapeutic target for early treatment or prevention of obesity-associated microvascular diseases, benefiting more than 80 million Americans. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.